NEW YORK, Nov. 22, 2010 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

The Hepatitis Market Outlook to 2015: Competitive landscape, market size, pipeline analysis and growth opportunities

http://www.reportlinker.com/p0330661/The-Hepatitis-Market-Outlook-to-2015-Competitive-landscape-market-size-pipeline-analysis-and-growth-opportunities.html

The Hepatitis Market Outlook to 2015 provides comprehensive coverage of the hepatitis market, incorporating disease overview and detailed epidemiological analyses of the various hepatitis types. This report makes a wide-ranging assessment of the marketed product portfolio, R&D pipeline, market share data, sales forecast and competitive landscape for the major players. Furthermore, it highlights the key market and R&D trends that may influence treatment sales; with a thorough analysis of the competitive dynamics of leading brands, in order to enable the reader to identify growing brands, key drug classes and leading players through 2015. The Hepatitis market may be classified as viral and non- viral hepatitis, on the basis of causative agents. Out of the six different kinds of viral hepatitis, A, B, C, D, E, and G, hepatitis A, B and C remains the most common infections prevalent across the globe.

Despite, a significant number of Hepatitis cases going unreported due to the asymptomatic nature of the disease about 1.4m cases of acute hepatitis A are reported every year while the number of chronic hepatitis B cases is 350m and hepatitis C is 170m. Hepatitis C has become one of the major focus areas for pharmaceutical companies because of high number of unmet needs for improved treatments. Although, most of the hepatitis infected population is in underdeveloped or developing countries, the market share of these countries in the global hepatitis market is relatively lower, due to the limited access to healthcare facilities resulting in significant un-diagnosed population. In terms of product pipeline, the hepatitis market has witnessed a lot of activity, with promising new drugs under late stages of development. The potential for market success is largely attributable to a large patient population, which requires long term treatment, and significant unmet need. Hepatitis C is the major indication in the hepatitis market with promising products in development. Presently, pegylated interferon commonly used in combination with the ribavirin is the standard of care for hepatitis C treatment.

This report provides in depth coverage of the hepatitis market, incorporating a disease overview and detailed epidemiological analyses of the various hepatitis types. It makes a thorough assessment of the marketed product portfolio, R&D pipeline, market share data, sales forecast and competitive landscape for the major players. It highlights the key market trends that will drive sales. rbhc0285

Scope of this research

* Develop insight into hepatitis patient potential with coverage of epidemiology of all major hepatitis types in the seven major pharmaceutical markets.

* Discover how recent events are affecting the performance of major products, and how their marketers are confronting competitive changes in the market.

* Compare the franchises of top pharmaceutical marketers, and evaluate how the market shares of the leading companies will change over the next 5 years.

* Gain up-to-date competitive intelligence on the hepatitis market and understand the major issues affecting its growth.

* Analyze the pipeline and marketed products of leading players and discover which will perform best through to 2015 with this report's sales forecasts.

Research and analysis highlights

The global hepatitis market in 2009 was valued at around $5bn, and is forecast to grow at a CAGR of more than 10% between 2009–15. These sales are being driven by products in the viral hepatitis class.

Sales in the hepatitis market are largely concentrated in the top 10 brands. These brands accounted for more than 80% of total sales. The leading product by sales in this market was Roche's Pegasys followed by Merck's Pegintron.

New pipeline compounds are expected to shorten treatment duration and improve the side effect and tolerability profile of treatment. The two most promising developmental products are telaprevir (J&J, Vertex) and boceprevir (Merck & Co) both indicated for hepatitis C.

Key reasons to purchase this research

* How is the prevalent population for hepatitis expected to change in the next five years?

* Which companies led the market for hepatitis therapies in 2009 and how are they forecast to perform through to 2015?

* What are the most promising products in development for the treatment of hepatitis and what are their forecast sales?

* How big is the generics market for hepatitis in the 7MM and which companies lead this market?

* Which vaccines lead the market for hepatitis vaccination and which companies market these products?

Table of Contents

About the author 2

Disclaimer 2

Executive summary 11

Overview and epidemiology of hepatitis 11

Global market analysis 12

Pipeline analysis 13

Competitive landscape 14

Scope and methodology 15

Scope 15

Methodology 15

Chapter 1 Overview and epidemiology of hepatitis 16

Summary 16

Introduction 17

Hepatitis A 17

Overview 17

Diagnosis and treatment 18

Epidemiology 19

Hepatitis B 20

Overview 20

Diagnosis and treatment 21

Epidemiology 22

Forecast epidemiology 23

Hepatitis C 25

Overview 25

Diagnosis and treatment 26

Epidemiology 27

Forecast epidemiology 28

Hepatitis D 30

Overview 30

Diagnosis and treatment 30

Hepatitis E 30

Overview 30

Diagnosis and treatment 31

Chapter 2 Global market analysis 32

Summary 32

Introduction 33

Market analysis by country 33

Market analysis by drug class 36

Leading brand dynamics 39

Pegasys (peginterferon alfa-2a) – Roche 40

Pegintron (peginterferon alfa-2b) – Merck 41

Baraclude (entecavir), – BMS 42

Hepsera (adefovir dipivoxil) – Gilead 43

Rebetol (ribavirin) – Merck 44

Viread (tenofovir disoproxil fumarate) – Gilead Sciences 44

Copegus (ribavirin) – Roche 45

Engerix B – GSK 45

Twinrix – GSK 46

Leading brands by drug class 47

Key recent events in the hepatitis market 49

Launch of Vertex's telaprevir expected to positively impact hepatitis market dynamics 49

BMS acquires ZymoGenetics for $885m 49

The FDA grants fast track designation to Pharmasset's PSI-7977 for the treatment of chronic HCV 49

Development program for therapeutic intranasal vaccine for the treatment of hepatitis B 50

Novartis discontinues the development of Joulferon/Zalbin on safety and efficacy concerns 50

GSK signs microRNA deal with Regulus for HCV 50

Government initiatives to curb the incidence of hepatitis 51

Generic hepatitis market in 7MM 51

Global hepatitis market sales forecast 54

Leading hepatitis drugs sales forecast 55

Chapter 3 Pipeline analysis 56

Summary 56

Introduction 57

Key trends in the R&D 57

Treatment-failure population to present significant opportunity 57

End stage renal disease (ESRD) patients expected to present high potential 58

Despite introduction of novel treatments, PEG/RBV will remain the standard of care 58

Promising developments in the hepatitis C pipeline 58

Product differentiation will hold the key to success in the hepatitis market 59

FDA introduced new guidelines for developing direct acting antiviral agents for HCV 59

Leading drugs in development 60

Profiles of key pipeline products 61

Phase III drugs 61

Telaprevir (VX-950) – Vertex/J&J/ Mitsubishi Tanabe 61

Boceprevir (SCH 503034) – Merck 64

Heplisav – Dynavax 66

Phase IIb drugs 68

Vaniprevir (MK-7009) – Merck 68

TMC435 (TMC435350) – Medivir/J&J 69

Alisporivir (Debio 025) – Debiopharm/ Novartis 70

Danoprevir (ITMN-191/RG7227) – Roche 72

BI 201335 – Boehringer Ingelheim 73

RG7128 – Roche/ Pharmasset 75

PEG-Interferon lambda (PEG-rIL-29) – BMS/ ZymoGenetics 76

Pipeline forecast of leading drugs in development 78

Chapter 4 Competitive landscape 79

Summary 79

Introduction 80

Competitive positioning of the leading players in the global hepatitis market 80

Roche 81

Sales focus by drug class 81

Regional sales distribution 82

Marketed product portfolio 84

Pipeline analysis 85

Strategic and growth analysis 86

Drivers of growth 86

Resistors of growth 87

Merck & Co. (Merck) 87

Sales focus by drug class 88

Regional sales distribution 88

Marketed product portfolio 90

Pipeline analysis 91

Strategic and growth analysis 92

Drivers of growth 92

Resistors of growth 92

GlaxoSmithKline (GSK) 93

Sales focus by drug class 93

Regional sales distribution 94

Marketed product portfolio 96

Pipeline analysis 98

Strategic and growth analysis 98

Drivers of growth 98

Resistors of growth 99

Bristol-Myers Squibb (BMS) 100

Sales focus by drug class 100

Regional sales distribution 101

Marketed product portfolio 101

Pipeline analysis 102

Strategic and growth analysis 103

Drivers of growth 103

Resistors of growth 104

Gilead Sciences (Gilead) 104

Sales focus by drug class 104

Regional sales distribution 105

Marketed product portfolio 106

Pipeline analysis 107

Strategic and growth analysis 108

Drivers of growth 108

Resistors of growth 109

Competitive positioning of leading generic players in hepatitis market in the 7MM 110

Chapter 5 Appendix 112

IMS data 112

Forecast factors 112

Epidemiology forecast 112

Market forecast 113

Glossary/Abbreviations 113

Table of figures

Figure 1: 7MM hepatitis market share by region (%), 2009 35

Figure 2: Relative positions of the 7MM in the global hepatitis market, 2009 35

Figure 3: Key drugs in late-stage development 60

Figure 4: Roche's global hepatitis sales by drug class ($m), 2009 82

Figure 5: Roche's hepatitis franchise market performance, 2006–09 84

Figure 6: Merck's global hepatitis sales by drug class ($m), 2009 88

Figure 7: Merck's hepatitis franchise market performance, 2006–09 90

Figure 8: GSK's hepatitis sales by drug class ($m), 2009 94

Figure 9: GSK's hepatitis franchise market performance, 2006–09 96

Figure 10: BMS' hepatitis sales by drug class ($m), 2009 100

Figure 11: Gilead's hepatitis sales by drug class ($m), 2009 104

Figure 12: Gilead's hepatitis franchise market performance, 2006–09 106

Figure 13: Competitive positioning of the top 10 generic players in the 7MM, 2009 111

Table of tables

Table 1: Worldwide endemicity of HAV infection 19

Table 2: Estimated prevalence of chronic hepatitis B across the 7MM, 2009 23

Table 3: Forecast epidemiology of chronic hepatitis B across the 7MM, 2009–15 24

Table 4: Estimated prevalence of chronic hepatitis C across 7MM, 2009 27

Table 5: Forecast epidemiology of chronic hepatitis C across 7MM, 2009–15 29

Table 6: Global hepatitis market by geography ($m), 2009 34

Table 7: Global hepatitis market sales by drug class, ($m), 2009 36

Table 8: Hepatitis market sales by drug class in the US, ($m), 2009 37

Table 9: Hepatitis market sales by drug class in Japan ($m), 2009 37

Table 10: Hepatitis market sales by drug class in EU5 ($m), 2009 38

Table 11: Hepatitis market sales by drug class in BRIC ($m), 2009 39

Table 12: Leading brands in the global hepatitis market ($m), 2009 40

Table 13: Leading brands in viral hepatitis ($m), 2009 47

Table 14: Leading brands in hepatitis vaccines ($m), 2009 48

Table 15: Leading brands in hepatitis immunoglobulin ($m), 2009 48

Table 16: Generic hepatitis market in 7MM ($m), 2009 52

Table 17: Generic hepatitis market sales by drug class in 7MM ($m), 2009 52

Table 18: Leading generic brands in the 7MM hepatitis market ($m), 2009 53

Table 19: Global hepatitis market sales forecast ($m), 2009–15 54

Table 20: Leading hepatitis brands sale forecast ($m), 2009 55

Table 21: An overview of telaprevir (VX-950) 61

Table 22: Details of Phase III studies of telaprevir 62

Table 23: An overview of boceprevir (SCH 503034) 64

Table 24: Details of Phase III studies of boceprevir 65

Table 25: Result of SPRINT-2 clinical trial in different cohorts 66

Table 26: An overview of Heplisav 67

Table 27: An overview of vaniprevir 68

Table 28: An overview of TMC435 69

Table 29: An overview of alisporivir 71

Table 30: An overview of danoprevir 73

Table 31: An overview of BI 201335 74

Table 32: An overview of RG7128 75

Table 33: An overview of PEG-Interferon lambda 77

Table 34: Sales forecast for leading drugs in development ($m), 2009–15 78

Table 35: Leading players in the global hepatitis market ($m), 2009 81

Table 36: Regional sales distribution of Roche in 7MM and BRIC ($m), 2009 83

Table 37: Performance of Roche's hepatitis products ($m), 2009 84

Table 38: Roche's hepatitis R&D pipeline, July 2010 86

Table 39: Regional sales distribution of Merck in 7MM and BRIC ($m), 2009 89

Table 40: Merck's hepatitis products portfolio ($m), 2009 91

Table 41: Merck's hepatitis R&D pipeline, July 2010 92

Table 42: Regional sales distribution of GSK in 7MM and BRIC ($m), 2009 95

Table 43: GSK's hepatitis products portfolio, ($m), 2009 98

Table 44: Regional sales distribution of BMS in 7MM and BRIC, ($m), 2009 101

Table 45: BMS's hepatitis products portfolio, ($m), 2009 102

Table 46: BMS's hepatitis R&D pipeline, May 2010 103

Table 47: Regional sales distribution of Gilead in 7MM and BRIC, ($m), 2009 105

Table 48: Gilead's hepatitis products portfolio, ($m), 2009 106

Table 49: Gilead's hepatitis R&D pipeline, July 2010 108

Table 50: Leading generic players in hepatitis market in the 7MM, ($m), 2009 110

To order this report:

Pathology Industry: The Hepatitis Market Outlook to 2015: Competitive landscape, market size, pipeline analysis and growth opportunities

Pathology Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

SOURCE Reportlinker

Back to top

RELATED LINKS
http://www.reportlinker.com